Exploration of Glutamatergic System With PET Radiotracer in Gilles de la Tourette Patients: Pilot Study (GlutaTour)

Toulouse University Hospital

Status: Enrolling

Conditions: Tourette Syndrome

Treatments: Diagnostic Test: Experimental MRI exam and PET scan exam with radiotracer

Study type: Interventional

Funder types: Other

Identifiers

NCT03681795

RC31/15/7836

2017-000816-40 (EudraCT Number)

Details and patient eligibility

About

Gilles de la Tourette syndrome is a neuropsychiatric disorder characterized by motor and vocal tics often associated with psychiatric comorbidities (obsessive compulsive disorder, anxiety and depressive syndrome, impulsivity). The pathophysiology of Gilles de la Tourette syndrome remains unclear.

Full description

Gilles de la Tourette syndrome is a neuropsychiatric disorder characterized by motor and vocal tics often associated with psychiatric comorbidities (obsessive compulsive disorder, anxiety and depressive syndrome, impulsivity). The pathophysiology of Gilles de la Tourette syndrome remains unclear. It would involve an alteration of striatal-cortico-thalamic cortical circuits resulting in dopaminergic dysfunction. But glutamatergic hypothesis is also discussed from pharmacological, biochemical and genetic arguments. Exploration of glutamatergic system can be done in humans in vivo using a new radiotracer: the [18F] FNM (Fluoroethylnormemantine), a derivative of memantine. In the present study, aim of the study 1) to show the glutamatergic system "in vivo" in patients with Tourette's syndrome and 2) to perform correlations between various motor and behavioral symptoms and the pattern of brain fixation for this radiotracer. To do that, a pilot study will be conducted in 12 patients with Tourette's who will be evaluated in terms of motor (tics) and behavioral (OCD, anxiety, depression, impulsivity) symptoms. Each patient will have a PET-scan exam and a brain MRI exam. Data analysis will be carried out from two different approaches: first by region of interest, and secondly, without topographic a priori with the Statistical Parametric Mapping (SPM) software.

Enrollment: 24 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Gilles de la Tourette syndrome according to the American Psychiatric association criteria (5 th ed, American Psychiatric association (APA), 2013)
• Aged 18 and over
• Patients treated with 2nd-generation neuroleptics for at least 3months
• Signed consent form

Exclusion criteria

• contraindications for MRI exam
• claustrophobia
• person under exclusive period for another study
• pregnant women
• patients under non-authorized treatment (1rst generation neuroleptics) or non-treated by neuroleptics

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

24 participants in 2 patient groups

patient

Experimental group

Description:

patients with Gilles de la Tourette syndrome

Treatment:

Diagnostic Test: Experimental MRI exam and PET scan exam with radiotracer

Control

Experimental group

Description:

healthy control

Treatment:

Diagnostic Test: Experimental MRI exam and PET scan exam with radiotracer